Finn
HIMS Digital Health · Telehealth · Subscription · Weight loss · Thesis updated November 15, 2026

Expanding globally with new partnerships but facing rising regulatory risks

01 Running thesis

A global shift beyond the shortage

Hims & Hers proved that its telehealth model could scale profitably in 2024. But the story shifted dramatically in early 2025 when the FDA resolved the semaglutide shortage. That event limited the company's ability to sell mass compounded weight loss drugs, forcing management to adapt quickly.

The bull case focuses on exceptional operational execution and AI driven operating leverage. Hims transitioned its weight loss users to 503A compounding based on clinical necessity and secured a direct supply of branded GLP-1 options from Novo Nordisk and Lilly. At the same time, the company aggressively expanded internationally, completing a $1.15 billion acquisition of Eucalyptus. The international segment is now pacing toward a $1 billion annual revenue run rate in 2027.

The bear case centers on execution, margin, and regulatory risks. A deliberate marketing pullback in the third quarter of 2026 resulted in a 100,000 sequential subscriber decline, highlighting a heavy reliance on customer acquisition spending. The FTC has officially filed a complaint against the company, presenting near-term litigation costs. Furthermore, moving weight loss users from high margin compounded products to branded options could pressure earnings.

Nov 2026▼Q3 2026 earnings showed a 100,000 sequential subscriber decline due to a deliberate marketing pullback. Management announced a new partnership with Lilly for Zepbound and launched its first controlled substances.
Aug 2026▼Q2 2026 earnings revealed the FTC escalated its non-public investigation into a formal complaint filed on July 29. Management highlighted three overseas markets from the Eucalyptus acquisition pacing above a $100 million run rate, and AI implementations reducing support tasks by 50 percent.
May 2026▲Q1 2026 earnings revealed a massive shift in the business. The company reorganized segments to US vs Rest of World following the $1.15 billion Eucalyptus acquisition, and reported fulfilling 125,000 branded Wegovy shipments in six weeks through a new Novo Nordisk partnership.
Feb 2025▼The 2024 10-K confirmed that the FDA resolved the semaglutide shortage on February 21, 2025. That moved the main GLP-1 risk from future worry to current test, even as Hims reported its first full year of profit.
Nov 2024▲Q3 2024 showed very strong growth, with revenue up 77% year over year and the non-GLP-1 subscriber base growing about 40%. Management also laid out plans for liraglutide and longer-term personalized weight loss offerings.
02 Business model

Subscriptions, personalization, and vertical integration

Hims & Hers generates revenue by connecting patients with licensed healthcare providers online and selling them prescription or wellness products. Most customers sign up for recurring deliveries, making subscription behavior central to the model. The company protects its market share through brand recognition and a scalable customer acquisition engine.

The business is evolving to control more of the value chain. Hims now operates FDA registered compounding facilities, a peptide manufacturing site, and an integrated lab testing business. By controlling the supply chain, the company aims to offer personalized solutions that standard pharmacies cannot match. Artificial intelligence initiatives are driving tangible operational leverage, handling routine work for 70 percent of weight loss subscribers and reducing support tasks materially.

The model breaks if customer acquisition costs spike, if churn rises, or if regulators limit key products. With the pivot to global markets, the company now faces the added complexity of managing direct-to-consumer health regulations in multiple foreign jurisdictions.

03 Product portfolio

From reactive conditions to proactive care

Growth engine

Weight loss

This specialty includes compounded options, generic liraglutide, and branded Wegovy and Zepbound. It drives massive growth but faces ongoing regulatory and margin scrutiny.

Option

Hormone therapy and lab testing

A push into proactive care featuring testosterone replacement therapy and comprehensive blood testing, designed to increase long term subscriber loyalty.

Option

Peptides Plus

Hims is launching new options like sermorelin and glutathione, while validating active pharmaceutical ingredients in its Menlo Park facility.

Cash cow

Sexual health

One of the original categories. It anchors the brand with reliable subscription revenue from treatments customers prefer to buy privately.

Steady

Dermatology and hair loss

These products fit the recurring delivery model perfectly. Personalized formulas help keep users engaged month after month.

Steady

Mental health

Digital access to mental health care adds breadth to the platform, though it must operate within strict prescribing rules.

04 Business segments

A new geographic split

United States Revenue85%growing fast
Rest of the World Revenue15%growing fast

Mix reflects the updated reporting structure introduced in Q1 2026 following major international acquisitions. The company now reports United States Revenue and Rest of the World Revenue instead of Online and Wholesale.

05 Risk factors

What could break the story

FTC litigation and regulatory scrutiny

High impact · High odds

The Federal Trade Commission filed a formal complaint against the company on July 29, 2026. This escalation from a non-public investigation introduces near-term litigation costs and potential long-term operational remedies.

We watchDevelopments in the FTC litigation and any legal settlement announcements.

Customer acquisition dependency

High impact · Medium odds

The company lost 100,000 net subscribers sequentially in the third quarter of 2026 after intentionally pulling back marketing spend. This highlights the business model's heavy reliance on continuous ad spending to maintain growth.

We watchSequential subscriber growth and sales and marketing expenses as a percentage of revenue.

Lower margin weight loss mix

High impact · Medium odds

Moving users from compounded semaglutide to branded Wegovy or Zepbound keeps them on the platform, but these branded drugs typically carry lower margins. If alternatives cost more to source, earnings quality could weaken.

We watchGross margin trends, Monthly Online Revenue per Average Subscriber, and management commentary on branded GLP-1 economics.

Integration of global acquisitions

High impact · Medium odds

The company spent $1.15 billion on Eucalyptus and bought other international brands. Integrating these operations across multiple countries brings massive execution risk and exposure to different health regulations.

We watchUpdates on the Eucalyptus integration, international segment margins, and Rest of the World revenue growth.
06 Quick answers

In one breath

How does Hims & Hers make money?

The company generates revenue primarily by selling prescription treatments, personalized health products, and lab testing through a recurring subscription model on its digital platform.

Why did the company change its business segments?

Following the $1.15 billion acquisition of Eucalyptus and other international brands, Hims restructured its reporting to focus on United States Revenue versus Rest of the World Revenue.

How did the FDA semaglutide shortage impact the stock?

Compounded semaglutide drove massive weight loss growth. The FDA resolved the shortage in February 2025, forcing Hims to pivot to 503A compounding and direct partnerships for branded GLP-1 drugs.

Is Hims & Hers profitable?

Yes. The company reached its first full year of profitability on a net income basis in 2024, reporting $126.0 million in net income.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 15, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Hims & Hers Q3 2026 earnings transcript
  2. Hims & Hers Q1 2026 Form 10-Q
08 Explore the industry

Comparable Household & Personal Products companies

Companies near Hims & Hers Health, Inc. in Finn's Household & Personal Products industry ranking.

Get started with Finn today